ClinicalTrials.gg
CompletedNCT05223920Updated Sep 22, 2025Results posted

An Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-7289-CTP-202/MK-3543-005)

A Phase 2 interventional study of Bomedemstat in Thrombocythemia, Essential and Primary Myelofibrosis, sponsored by Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA). Completed at 19 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-22.

Sponsored by Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
81
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 149 studies in Thrombocythemia, Essential with a site in United States — 18 open to participants now, 32 under way, 6 of them phase 3. Thrombocythemia, Essential · United States.

Enrollment
35th of 120
81 · median 45
Started
2021
with 2 others
Phase 2
49 of 149
6 open now
Registered
131st of 149
by date

Among the 149 studies in Thrombocythemia, Essential with a site in United States, this one is the 35th largest by enrollment of the 120 interventional ones that give a count, is one of 3 that started in 2021, is one of 49 in phase 2, and was the 131st registered.

Thrombocythemia, Essential

229 studies on the registry are indexed under Thrombocythemia, Essential; 38 are open to participants now.

Browse Thrombocythemia, Essential studies →

Open to participants now

18 of the 149 studies in Thrombocythemia, Essential with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 34 Thrombocythemia, Essential studies recruiting now, 30 (88%) set no upper age limit and 3 (9%) stop at 75 or younger; 5 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 149 studies in Thrombocythemia, Essential with a site in United States, or all of them as a file.
02

Study summary

This is a multi-center, open-label extension study to assess the long-term safety and efficacy of bomedemstat administered orally once daily in participants with a Myeloproliferative Neoplasm (MPN) who participated in a prior bomedemstat study such as, but not limited to, IMG-7289-CTP-102/MK-3543-002 (NCT03136185) and IMG-7289-CTP-201/MK-3543-003 (NCT04254978) (referred to hereafter as 'feeder studies').

03

Conditions studied

  • Thrombocythemia, Essential
  • Primary Myelofibrosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Inclusion Criteria include, but are not limited to:

  • Has completed at least one Treatment Period (TP) in a prior bomedemstat Myeloproliferative Neoplasms (MPN) protocol (such as, but not limited to, IMG-7289-CTP-102/MK-3543-002 (NCT03136185) and IMG-7289-CTP-201/MK-3543-003) (NCT04254978).
  • In the estimation of the Investigator, the risk-benefit favors continued dosing with bomedemstat.

Exclusion criteria

Exclusion Criteria:

Exclusion Criteria include, but are not limited to:

  • Ongoing participation in another study (except observational studies).
  • A history of non-compliance in a prior bomedemstat study (excluding dose suspensions that were medically warranted).
  • Current use of a prohibited medication (e.g., romiplostim).
  • Medical, psychiatric, cognitive, or other conditions that, in the Investigator's opinion, compromise the patient's safety, ability to give , or comply with the trial protocol.
  • Is pregnant or breastfeeding or plan to become pregnant or breastfeed during the study.
  • Women of (WOCBP) and fertile men unwilling to agree to use an approved method of from time of enrollment until 14 days after last bomedemstat dose.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
81 participants (actual)

Study arms

  • Experimental
    Bomedemstat

    All participants will receive bomedemstat via oral capsule daily for 169 days with additional treatment continuing in patients deriving clinical benefit.

    Drug: Bomedemstat

Interventions

  • Capsule (oral)

    Also known as: IMG-7289, MK-3543

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Experience an Adverse Event (AE)

    An AE is any undesirable physical, psychological or behavioral effect experienced by a participant during participation in an investigational study, in conjunction with the use of the drug or biologic, whether or not product-related. This includes any clinically significant abnormalities in vital signs and lab values, untoward signs or symptoms experienced by the participant from the time of first dose with bomedemstat under this protocol until completion of the study. The percentage of participants who experienced an AE is presented.

    Time frame: Up to ~32 months

  2. Percentage of Participants Who Discontinue Study Intervention Due to an AE

    An AE is any undesirable physical, psychological or behavioral effect experienced by a participant during participation in an investigational study, in conjunction with the use of the drug or biologic, whether or not product-related. This includes any clinically significant abnormalities in vital signs and lab values, untoward signs or symptoms experienced by the participant from the time of first dose with bomedemstat under this protocol until completion of the study. The percentage of participants who discontinued study intervention due to an AE is presented.

    Time frame: Up to ~32 months

  3. Mean Spleen Volume Reduction Based on Spleen Volume Measured by MRI in Participants With MF.

    Mean Spleen volume reduction (mL) in participants with MF as measured by central laboratory imaging analysis of MRI (or CT where applicable) approximately every 48 weeks. Per protocol only participants with MF were analyzed for this outcome measure. The change in spleen volume from baseline is presented.

    Time frame: Baseline and Days 169, 339, 509, 679, 849 and 924

  4. Percentage of Participants With ET Who Achieve a Reduction of Platelet Counts to <= 400 K/uL (400 x 10^9/L) in the Absence of New Thromboembolic Events

    Blood samples were taken at designated time points to determine platelet count. Percentage of participants with ET who achieve a reduction of platelet counts to \<= 400 K/uL (400 x 10\^9/L) in the absence of new thromboembolic events is presented.

    Time frame: Baseline and Days 29, 57, 85, 113, 141, 169, 198, 226, 254, 282, 310, 338, 367, 395, 423, 451, 479, 507, 536, 564, 592, 620, and 648

07

Results

Posted Sep 22, 2025

Participant flow

Participants with Myeloproliferative Neoplasms (MPNs) who participated in a prior bomedemstat study such as, but not limited to, IMG-7289-CTP-102/MK-3543-002 (NCT03136185) and IMG-7289-CTP-201/MK-3543-003 (NCT04254978) (referred to hereafter as 'feeder studies') were included in the recruitment.

Participant flow — Overall Study
MilestoneEssential Thrombocythemia (ET)Myelofibrosis (MF)
Started5229
Completed00
Not completed5229
Withdrew: Adverse event63
Withdrew: Death20
Withdrew: Disease progression12
Withdrew: Physician decision12
Withdrew: Sponsor decision119
Withdrew: Transferred to extension study mk-3543-017 (nct06351631)297
Withdrew: Subject decision10
Withdrew: Withdrawal by subject16

Outcome measures

PrimaryPercentage of Participants Who Experience an Adverse Event (AE)

An AE is any undesirable physical, psychological or behavioral effect experienced by a participant during participation in an investigational study, in conjunction with the use of the drug or biologic, whether or not product-related. This includes any clinically significant abnormalities in vital signs and lab values, untoward signs or symptoms experienced by the participant from the time of first dose with bomedemstat under this protocol until completion of the study. The percentage of participants who experienced an AE is presented.

Time frame:
Up to ~32 months
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Experience an Adverse Event (AE)
Percentage of ParticipantsEssential Thrombocythemia (ET)Myelofibrosis (MF)
Percentage of Participants Who Experience an Adverse Event (AE)98.1100.0
PrimaryPercentage of Participants Who Discontinue Study Intervention Due to an AE

An AE is any undesirable physical, psychological or behavioral effect experienced by a participant during participation in an investigational study, in conjunction with the use of the drug or biologic, whether or not product-related. This includes any clinically significant abnormalities in vital signs and lab values, untoward signs or symptoms experienced by the participant from the time of first dose with bomedemstat under this protocol until completion of the study. The percentage of participants who discontinued study intervention due to an AE is presented.

Time frame:
Up to ~32 months
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Discontinue Study Intervention Due to an AE
Percentage of ParticipantsEssential Thrombocythemia (ET)Myelofibrosis (MF)
Percentage of Participants Who Discontinue Study Intervention Due to an AE15.410.3
PrimaryMean Spleen Volume Reduction Based on Spleen Volume Measured by MRI in Participants With MF.

Mean Spleen volume reduction (mL) in participants with MF as measured by central laboratory imaging analysis of MRI (or CT where applicable) approximately every 48 weeks. Per protocol only participants with MF were analyzed for this outcome measure. The change in spleen volume from baseline is presented.

Time frame:
Baseline and Days 169, 339, 509, 679, 849 and 924
Reported as:
Mean · mL
Mean Spleen Volume Reduction Based on Spleen Volume Measured by MRI in Participants With MF.
mLEssential Thrombocythemia (ET)Myelofibrosis (MF)
Day 169—-101.570 ± 92.6876
Day 339—-67.645 ± 249.0079
Day 509—-5.920 ± 143.1692
Day 679—-61.000 ± 396.2520
Day 849—-38.840 ± NA
Day 924—80.575 ± 10.3308
PrimaryPercentage of Participants With ET Who Achieve a Reduction of Platelet Counts to <= 400 K/uL (400 x 10^9/L) in the Absence of New Thromboembolic Events

Blood samples were taken at designated time points to determine platelet count. Percentage of participants with ET who achieve a reduction of platelet counts to \<= 400 K/uL (400 x 10\^9/L) in the absence of new thromboembolic events is presented.

Time frame:
Baseline and Days 29, 57, 85, 113, 141, 169, 198, 226, 254, 282, 310, 338, 367, 395, 423, 451, 479, 507, 536, 564, 592, 620, and 648
Reported as:
Number · Percentage of participants
Percentage of Participants With ET Who Achieve a Reduction of Platelet Counts to <= 400 K/uL (400 x 10^9/L) in the Absence of New Thromboembolic Events
Percentage of participantsEssential Thrombocythemia (ET)Myelofibrosis (MF)
Day 2977.1 (62.7 to 88.0)—
Day 5772.9 (58.2 to 84.7)—
Day 8572.0 (57.5 to 83.8)—
Day 11378.4 (64.7 to 88.7)—
Day 14191.8 (80.4 to 97.7)—
Day 16989.4 (76.9 to 96.5)—
Day 19886.7 (73.2 to 94.9)—
Day 22681.8 (67.3 to 91.8)—
Day 25479.5 (64.7 to 90.2)—
Day 28275.0 (59.7 to 86.8)—
Day 31081.4 (66.6 to 91.6)—
Day 33883.7 (69.3 to 93.2)—
Day 36776.2 (60.5 to 87.9)—
Day 39578.0 (62.4 to 89.4)—
Day 42380.0 (64.4 to 90.9)—
Day 45182.1 (66.5 to 92.5)—
Day 47975.7 (58.8 to 88.2)—
Day 50796.2 (80.4 to 99.9)—
Day 53694.7 (74.0 to 99.9)—
Day 56486.7 (59.5 to 98.3)—
Day 59272.7 (39.0 to 94.0)—
Day 62085.7 (42.1 to 99.6)—
Day 64883.3 (35.9 to 99.6)—

Adverse events

Collected over Death and adverse events up to ~32 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Essential Thrombocythemia (ET)2/52 (3.8%)19/52 (36.5%)45/52 (86.5%)
Myelofibrosis (MF)0/29 (0%)12/29 (41.4%)28/29 (96.6%)
Most frequent serious events
Showing 10 of 51
Most frequent serious events
EventEssential Thrombocythemia (ET)Myelofibrosis (MF)
ThrombocytopeniaBlood and lymphatic system disorders3/522/29
Post procedural haemorrhageInjury, poisoning and procedural complications0/522/29
PneumoniaInfections and infestations3/521/29
Skin lacerationInjury, poisoning and procedural complications2/520/29
Acute kidney injuryRenal and urinary disorders2/520/29
Febrile neutropeniaBlood and lymphatic system disorders0/521/29
Cardiac failure congestiveCardiac disorders0/521/29
Supraventricular tachycardiaCardiac disorders0/521/29
Food poisoningGastrointestinal disorders0/521/29
Gingival bleedingGastrointestinal disorders0/521/29
Most frequent other events
Showing 10 of 75
Most frequent other events
EventEssential Thrombocythemia (ET)Myelofibrosis (MF)
ArthralgiaMusculoskeletal and connective tissue disorders15/5214/29
ThrombocytopeniaBlood and lymphatic system disorders6/5212/29
COVID-19Infections and infestations6/5211/29
AnaemiaBlood and lymphatic system disorders10/527/29
DiarrhoeaGastrointestinal disorders5/527/29
Gingival bleedingGastrointestinal disorders3/527/29
ContusionInjury, poisoning and procedural complications4/526/29
Bone painMusculoskeletal and connective tissue disorders0/526/29
Rectal haemorrhageGastrointestinal disorders0/525/29
DizzinessNervous system disorders8/524/29

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Essential Thrombocythemia (ET)Myelofibrosis (MF)Total
Mean65.8 ± 11.0165.3 ± 9.6865.6 ± 10.49
Sex: Female, Male
Sex: Female, Male(Participants)Essential Thrombocythemia (ET)Myelofibrosis (MF)Total
Female291443
Male231538
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Essential Thrombocythemia (ET)Myelofibrosis (MF)Total
Hispanic or Latino112
Not Hispanic or Latino512879
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Essential Thrombocythemia (ET)Myelofibrosis (MF)Total
American Indian or Alaska Native000
Asian141529
Native Hawaiian or Other Pacific Islander000
Black or African American314
White351348
More than one race000
Unknown or Not Reported000
Baseline Spleen Volume by Magnetic resonance imaging/computerized tomography (MRI/CT) in mL
Baseline Spleen Volume by Magnetic resonance imaging/computerized tomography (MRI/CT) in mL(mL)Essential Thrombocythemia (ET)Myelofibrosis (MF)Total
Median—835.21 (98.88 to 3085.92)835.21 (98.88 to 3085.92)
Baseline Platelet Counts in thousands per microliter (10^3 cells/μL)
Baseline Platelet Counts in thousands per microliter (10^3 cells/μL)(10^3 cells/μL)Essential Thrombocythemia (ET)Myelofibrosis (MF)Total
Mean380.4 ± 207.44190.5 ± 209.64312.4 ± 226.29
08

Study locations

19 sites
  • University of Miami Leonard M. Miller
    Miami, Florida 33136, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • UMPC Hillman Cancer Center
    Pittsburgh, Pennsylvania 15232, United States
  • Fred Hutchinson Cancer Center
    Seattle, Washington 98109, United States
  • Royal Prince Alfred Hospital
    Camperdown, New South Wales 2050, Australia
  • Royal North Shore Hospital
    Saint Leonards, New South Wales 2065, Australia
  • Gold Coast Hospital and Health Service
    Southport, Queensland 4215, Australia
  • Royal Adelaide Hospital
    Adelaide, South Australia 5000, Australia
  • Universittsklinikum Essen
    Essen, 45147, Germany
  • Queen Mary Hospital
    Hong Kong, Hong Kong
  • Ospedale di Circolo-a Fondazione Macchi
    Varese, VA 2100, Italy
  • Azienda Ospedaliera SS. Antonio
    Alessandria, 15121, Italy
  • Azienda Ospedaliero-Universitaria Careggi - S.O.D. Ematologia (CRIMM)
    Florence, 50134, Italy
  • Azienda Ospedaliero Universitaria di Bologna
    Pavia, 27100, Italy
  • Middlemore Clinical Trials
    Papatoetoe, Aukland 2025, New Zealand
  • Waitemata District Health Board
    Takapuna, Aukland 0622, New Zealand
  • University College London Hospitals NHS Foundation Trust
    London, NW1 12G, United Kingdom
  • Guy's and Saint Thomas' NHS Foundation Trus
    London, SE1 9RT, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2021 to primary completion in Aug 2024, 32 months.

Results were first posted in Sep 2025, 1 year 1 month after primary completion.

Of 27 phase 2 interventional studies under Thrombocythemia, Essential, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 141. This study's 32 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2021
First posted
Feb 4, 2022
StartActual
Dec 15, 2021
Primary completionActual
Aug 22, 2024
CompletionActual
Aug 22, 2024
Results first posted
Sep 22, 2025
Last update
Sep 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05223920
Responsible party
Sponsor
First posted
Feb 4, 2022
Start date
Dec 15, 2021
Primary completion
Aug 22, 2024
Completion
Aug 22, 2024
Results posted
Sep 22, 2025
Last update
Sep 22, 2025

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bomedemstat

Start the discussion